Crown Bioscience

Crown Bioscience

Crown Bioscience operates as a full-service contract research organization (CRO) specializing in translational oncology and immuno-oncology. The firm provides preclinical and translational services to biotech and pharmaceutical companies worldwide. It maintains laboratory and office locations across North America, Europe, and Asia. The company's founding year and founding principals are not enumerated in the primary research sources consulted. The company's service offerings encompass a wide portfolio of preclinical models. These include patient-derived xenografts (PDX), cell line derived xenografts (CDX), syngeneic models, tumor homograft models, and humanized genetically modified mouse models. The company also deploys specialized in vitro models, including organoid samples derived from HUB protocols. The company's platform allows researchers to select from over 600 PDX organoid models, over 1000 cancer cell lines, and over 200 CDX models. The stated corporate mission is to support the FDA's shift toward reducing animal testing requirements for monoclonal antibodies and other therapies through the FDA Modernization Act 2.0. The company has not disclosed data on total professionals, annual revenue, or total asset values. It operates over 15 office and laboratory facilities across the United States, the United Kingdom, the Netherlands, Germany, China, Japan, South Korea, India, and Singapore. No recent operational event in the past 24 months was identified in the primary sources reviewed. Crown Bioscience's structural distinction is its exclusive focus on translational oncology CRO services. The company markets a proprietary multi-model search tool that enables clients to compare and select from several model types simultaneously. The company has not disclosed whether it operates as a subsidiary of any larger corporate entity or unrelated financial sponsor.